HOLX Hologic Inc

Price (delayed)

$79.06

Market cap

$19.46B

P/E Ratio

26.09

Dividend/share

N/A

EPS

$3.03

Enterprise value

$19.72B

Hologic, Inc. is a medical technology company primarily focused on women’s health; it sells medical devices for diagnostics, surgery, and medical imaging. In late November 2013, activist investor Carl Icahn ...

Highlights
Hologic's quick ratio has increased by 45% YoY and by 6% QoQ
HOLX's equity is up by 11% year-on-year and by 4.1% since the previous quarter
Hologic's net income has shrunk by 51% YoY and by 24% QoQ
The EPS has dropped by 51% year-on-year and by 23% since the previous quarter

Key stats

What are the main financial stats of HOLX
Market
Shares outstanding
246.12M
Market cap
$19.46B
Enterprise value
$19.72B
Valuations
Price to book (P/B)
3.68
Price to sales (P/S)
4.83
EV/EBIT
19.48
EV/EBITDA
14.14
EV/Sales
4.86
Earnings
Revenue
$4.06B
EBIT
$1.01B
EBITDA
$1.4B
Free cash flow
$840.5M
Per share
EPS
$3.03
Free cash flow per share
$3.39
Book value per share
$21.5
Revenue per share
$16.38
TBVPS
$19.98
Balance sheet
Total assets
$9.45B
Total liabilities
$4.15B
Debt
$2.84B
Equity
$5.3B
Working capital
$3.26B
Liquidity
Debt to equity
0.54
Current ratio
4.41
Quick ratio
3.45
Net debt/EBITDA
0.19
Margins
EBITDA margin
34.4%
Gross margin
55.9%
Net margin
18.6%
Operating margin
22%
Efficiency
Return on assets
8.1%
Return on equity
14.9%
Return on invested capital
24.3%
Return on capital employed
11.9%
Return on sales
25%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

HOLX stock price

How has the Hologic stock price performed over time
Intraday
-0.11%
1 week
0.04%
1 month
-5.85%
1 year
4.04%
YTD
5.68%
QTD
-2.03%

Financial performance

How have Hologic's revenue and profit performed over time
Revenue
$4.06B
Gross profit
$2.27B
Operating income
$891.5M
Net income
$753M
Gross margin
55.9%
Net margin
18.6%
Hologic's operating income has shrunk by 56% YoY and by 27% QoQ
Hologic's net income has shrunk by 51% YoY and by 24% QoQ
The operating margin has contracted by 42% YoY and by 20% from the previous quarter
The company's net margin fell by 35% YoY and by 16% QoQ

Growth

What is Hologic's growth rate over time

Valuation

What is Hologic stock price valuation
P/E
26.09
P/B
3.68
P/S
4.83
EV/EBIT
19.48
EV/EBITDA
14.14
EV/Sales
4.86
The EPS has dropped by 51% year-on-year and by 23% since the previous quarter
The stock's price to earnings (P/E) is 50% more than its last 4 quarters average of 17.4
HOLX's price to book (P/B) is 25% lower than its 5-year quarterly average of 4.9 but 5% higher than its last 4 quarters average of 3.5
HOLX's equity is up by 11% year-on-year and by 4.1% since the previous quarter
HOLX's price to sales (P/S) is 31% higher than its 5-year quarterly average of 3.7 and 24% higher than its last 4 quarters average of 3.9
The revenue has contracted by 25% YoY and by 9% from the previous quarter

Efficiency

How efficient is Hologic business performance
The ROE has plunged by 58% YoY and by 26% from the previous quarter
Hologic's return on assets has shrunk by 53% YoY and by 24% QoQ
HOLX's return on invested capital is down by 47% year-on-year and by 23% since the previous quarter
The return on sales has declined by 34% year-on-year and by 14% since the previous quarter

Dividends

What is HOLX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HOLX.

Financial health

How did Hologic financials performed over time
The total assets is 128% higher than the total liabilities
Hologic's current ratio has increased by 48% YoY and by 4.8% from the previous quarter
Hologic's quick ratio has increased by 45% YoY and by 6% QoQ
The company's debt is 46% lower than its equity
Hologic's debt to equity has decreased by 17% YoY and by 3.6% from the previous quarter
HOLX's equity is up by 11% year-on-year and by 4.1% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.